Aids Malignancy Consortium

This study tested a DNA-based vaccine called VGX-3100 in 44 HIV-positive adults with high-grade anal precancer caused by HPV types 16 or 18. The vaccine was given with a small electrical pulse (electroporation) to help cells absorb it, aiming to train the immune system to clear t…

This study tested whether the HPV vaccine can reduce high-grade cervical lesions (precancerous changes) in 536 women living with HIV. Participants received either the HPV vaccine or a placebo, and researchers tracked new lesions over one to two years. The goal was to see if the v…

This study tested the drug nelfinavir, originally used for HIV, in 36 adults with Kaposi sarcoma (a type of skin cancer). The goal was to see if it could shrink or eliminate skin lesions. Participants took standard or high doses, and researchers measured how many responded to tre…

This study tested a drug called pomalidomide in 26 HIV-positive people with Kaposi sarcoma, a type of skin cancer, in Sub-Saharan Africa. The drug works by boosting the immune system and blocking tumor growth. The goal was to see if it could shrink tumors and how safe it was. Thi…

This study looked at whether removing small, early-stage anal cancers with local surgery alone is safe and effective for people with HIV. The goal was to see if this less invasive approach could avoid the need for radiation or chemotherapy. Sixteen participants were followed for …

This study looked at how well people with AIDS-related Kaposi sarcoma felt during treatment with two chemotherapy drugs, vincristine and bleomycin. Ten participants in Tanzania filled out quality-of-life surveys over three months. The goal was to understand how the treatment affe…

This study looked back at 30 people with HIV who were treated with CAR T-cell therapy for certain blood cancers like lymphoma or leukemia. Researchers collected standard medical data to see how often side effects occurred and how the immune system changed over time. The goal was …